NHS Framework Agreement for the Supply of Direct Oral Anticoagulant (DOAC) Medicines for the NHS in England
key details
| Value | £3,185,000,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 +1 more |
| Region | Yorkshire and the Humber |
| Deadline | 3 Sept 2021 |
| Procedure | open |
| OCID | ocds-h6vhtk-02cb5f |
Awards (3)
This procurement was awarded to 3 suppliers. Values shown are per-award; the notice total is £3,185,000,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Bayer Ltd shared | · | · | active |
| Bristol Myers Squibb shared | · | · | active |
| Daiichi Sankyo UK Ltd shared | · | · | active |
description
NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England. Also known as Novel Oral Anticoagulants (NOACs).Period of Framework: 01/01/2022 - 31/04/2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 39 months)
notice history
4 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 22 Jul 2021 | Contract notice (F02) | Earlier regulations | 017393-2021 |
| 10 Aug 2021 | Corrigendum (F14) | Earlier regulations | 019266-2021 |
| 25 Nov 2021 | Contract award notice (F03) | Earlier regulations | 029382-2021 |
| 26 Nov 2021 | Corrigendum (F14) | Earlier regulations | 029421-2021 |
more from The NHS Commissioning Board (operating under the name of NHS England)
- Implementation of GP referral pathway to NHS CPCS · £1,700,000 · 12 May 2022
- NHS England and NHS Improvement - Independent Clinical Reviews into Deaths in Custody – South East Health & Justice, Detained Estates · 29 Apr 2022
- Provision of Benchmarking Performance Against the Learning Disability Improvement Standards for NHS Trusts · £800,000 · 18 Mar 2022
- PMO Support for the Cancer Healthcare and AI in Health and Care Programmes · £2,000,000 · 3 Mar 2022
- NHS Framework for the North of England, Branded Medicine · £863,999,552 · 1 Mar 2022
- NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual · £216,078,796 · 22 Feb 2022
- NHS National Generic Pharmaceuticals Wave 13 · £1,637,875,080 · 14 Jan 2022
- Targeted Lung Health Check Programme: External Quality Assurance of Radiologists · £800,000 · 22 Dec 2021
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.